CLINICAL TRIALS PROFILE FOR BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

All Clinical Trials for Bacteriostatic Sodium Chloride 0.9% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00067340 ↗	Caries Transmission Prevention in Alaska Native Infants	Terminated	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 3	2003-04-01	The purpose of this study is to conduct a community based, randomized control trial to determine if the use of chlorhexidine mouth rinse and xylitol-sweetened chewing gum will reduce the vertical transmission of caries between Alaska Native mothers to their infants.
NCT00067340 ↗	Caries Transmission Prevention in Alaska Native Infants	Terminated	University of Washington	Phase 3	2003-04-01	The purpose of this study is to conduct a community based, randomized control trial to determine if the use of chlorhexidine mouth rinse and xylitol-sweetened chewing gum will reduce the vertical transmission of caries between Alaska Native mothers to their infants.
NCT00111956 ↗	Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome	Completed	Massachusetts General Hospital	Phase 2/Phase 3	2004-04-01	Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00111956 ↗	Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2/Phase 3	2004-04-01	Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.

Clinical Trial Conditions for Bacteriostatic Sodium Chloride 0.9% In Plastic Container

Condition Name

Condition Name for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Intervention	Trials
Acne Vulgaris	3
Anesthesia, Local	2
Healing Surgical Wounds	2
Pneumonia	2

Condition MeSH

Condition MeSH for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Intervention	Trials
Infections	4
Infection	4
Pneumonia	3
Acne Vulgaris	3

Clinical Trial Locations for Bacteriostatic Sodium Chloride 0.9% In Plastic Container

Trials by Country

Trials by Country for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Location	Trials
United States	16
Egypt	5
France	3
India	3
Netherlands	3

Trials by US State

Trials by US State for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Location	Trials
California	4
Ohio	2
Minnesota	2
Texas	1
Delaware	1

Clinical Trial Progress for Bacteriostatic Sodium Chloride 0.9% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase	Trials
Phase 4	23
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase	Trials
Completed	17
Not yet recruiting	13
Unknown status	8

Clinical Trial Sponsors for Bacteriostatic Sodium Chloride 0.9% In Plastic Container

Sponsor Name

Sponsor Name for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Sponsor	Trials
Ain Shams Maternity Hospital	2
University of California, San Francisco	2
Assiut University	2

Sponsor Type

Sponsor Type for Bacteriostatic Sodium Chloride 0.9% In Plastic Container
Sponsor	Trials
Other	65
Industry	10
NIH	2